Select Bibliography

Filter by any of these (after searching):

Jung, Sin-Ho

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 44 items

Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016

Manuscript - Primary - Preliminary - Prevention - CALGB-70806

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50303

Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)

Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017

Abstract - Primary - Primary - Lymphoma - CALGB-50904

Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)

Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50904

CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells

Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014

Manuscript - Primary - Primary - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

Fulton, Noreen , Johnson, Jeffrey , Kaplan, Lawrence D. , Koval, Greg ... - ASH - Blood - 2013

Abstract - Secondary - Primary - Lymphoma - CALGB-50403

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Furman, Richard R. , Grossbard, Michael L. , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2011

Manuscript - Primary - Primary - Lymphoma - CALGB-9254

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

Grant, Barbara W , Jung, Sin-Ho , Johnson, Jeffrey L ... - - Cancer - 2013

Manuscript - Primary - Primary - Lymphoma - CALGB-50701

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

Hsi, Eric D. , Jung, Sin-Ho , Lai, Raymond , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2008

Manuscript - Secondary-not-in-original - Primary - Lymphoma - CALGB-59909

Bortezomib Maintenance (Bm) Versus Consolidation (Bc) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (Asct) For Untreated Mantle Cell Lymphoma (Mcl): CALGB 50403

Kaplan, Lawrence D. , Stock, Wendy , Jung, Sin-Ho , Bartlett, Nancy ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - CALGB-50403

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Kostakoglu, Lale , Schöder, Heiko , Johnson, Jeffrey L ... - - Leuk. Lymphoma - 2012

Manuscript - Secondary - Primary - Lymphoma - CALGB-50203

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.

Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-59804

Early relapse of follicular lymphoma after rituximab-based biologic doublet upfront therapy is associated with increased risk of death: a combined analysis from CALGB/Alliance Studies 50402, 50701 and 50803

Lansigan, Frederick , Barak, Ian , Pitcher, Brandelyn , Jung, Sin-Ho ... - ASH - Blood - 2016

Abstract - Secondary-not-in-original - Meta-Analysis - Lymphoma - CALGB-50402 , CALGB-50701 , CALGB-50803

Comparison of results from three different density assessment methods on mammographic density (MD) in a screening patients receiving vitamin D (Vit D): Results of CALGB 70806 (Alliance)

Le-Petross, Huong T. , Seisler, Drew K. , Kontos, Despina ... - RSNA - - 2018

Abstract - Secondary - Primary - Prevention - CALGB-70806

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

Leonard, John P. , Jung, Sin-Ho , Johnson, Jeffrey ... - - J. Clin. Oncol - 2015

Manuscript - Primary - Primary - Lymphoma - CALGB-50401

Alliance A051202: A Phase I Trial of Lenalidomide, Rituximab and GS-1101 (Idelalisib) in recurrent follicular lymphoma

Leonard, John P. , Jung, Sin-ho ... - ICML - Hematol Oncol - 2013

Abstract - No-Endpoint - Trial-Description-Only - Lymphoma - A051202

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Martin, Peter , Jung, Sin-Ho , Johnson, Jeffrey L. , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary - Primary - Lymphoma - CALGB-50803

Final results of CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Martin, Peter , Jung, Sin-Ho , Pitcher, Brandy , Bartlett, Nancy ... - ICML - Hemato Oncol - 2017

Abstract - Primary - Long-Term-Followup - Lymphoma - CALGB-50803

Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017

Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Morrison, Vicki A. , Jung, Sin-Ho , Johnson, Jeffrey , LaCasce, Ann ... - - Leuk. Lymphoma - 2015

Manuscript - Primary - Primary - Lymphoma - CALGB-50501

A Randomized Trial of Diet in Men with Early Stage Prostate Cancer on Active Surveillance: Rationale and Design of the Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance])

Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - Contemp Clin Trials - 2014

Manuscript - No-Endpoint - Trial-Description-Only - Prevention - CALGB-70807

The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer

Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - BJU Int. - 2018

Manuscript - Secondary-not-in-original - Preliminary - Prevention - CALGB-70807

Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)

Rosenbaum, Cara A. , Pitcher, Brandelyn , Bartlett, Nancy L ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - CALGB-50901

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Rosenbaum, Cara A , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Br. J. Haematol. - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50901

High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial.

Scott, David W. , Pitcher, Brandelyn , Liu, Yi Tian , Boyle, Merrill ... - ICML - Hematol Oncol - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-50403

Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014

Abstract - Secondary - Meta-Analysis - Lymphoma - A051201 , A051202

Safety and Tolerability of Idelalisib, Lenalidomide, and Rituximab in Relapsed and Refractory Lymphoma: Alliance A051201 and A051202 Phase I Trials

Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - - Lancet Haematol - 2017

Manuscript - Primary - Primary - Lymphoma - A051201 , A051202

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

Smith, Sonali M. , Schöder, Heiko , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2013

Manuscript - Primary - Primary - Lymphoma - CALGB-50602

Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy

Sohani, Aliyah R. , Maurer, Matthew J. , Giri, Sharmila ... - - Am J Surg Pathol - 2021

Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Straus, David J. , Johnson, Jeffrey L. , LaCasce, Ann S. ... - - Blood - 2011

Manuscript - Primary - Primary - Lymphoma - CALGB-50203

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Straus, David J. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2018

Manuscript - Primary - Primary - Lymphoma - CALGB-50604

Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015

Abstract - Primary - Preliminary - Lymphoma - CALGB-50604

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)☆

Tallarico, Michael , Foster, Jared C. , Seisler, Drew ... - - J Geriatr Oncol - 2018

Manuscript - Secondary - Primary - Older Adult - A151611

Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617

Thanarajasingam, Gita , Dueck, Amylou , Novotny, Paul J. ... - ICML - Hematol Oncol - 2017

Abstract - Primary - Primary - Health Outcome - CALGB-50401 , A151617

Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance)

Thanarajasingam, Gita , Leonard, John P. , Witzig, Thomas E. ... - - Lancet Haematol - 2020

Manuscript - No-Endpoint - Other - Health Outcome - A151617 , CALGB-50401

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Ujjani, Chaitra S. , Jung, Sin-Ho , Pitcher, Brandelyn ... - - Blood - 2016

Manuscript - Primary - Primary - Lymphoma - A051103

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Ujjani, Chaitra , Jung, Sin-Ho , Pitcher, Brandelyn , Martin, Peter ... - ASH - Blood - 2015

Abstract - Primary - Primary - Lymphoma - A051103

Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303

Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016

Abstract - Primary - Primary - Lymphoma - CALGB-50303

The influence of vitamin D on mammographic density: results from CALGB 70806 (Alliance)

Wood, Marie , Liu, Heshan , Storrick, Elizabeth , Zahrieh, David ... - - Cancer Prev Res (Phila) - 2021

Manuscript - Primary - Primary - Prevention - CALGB-70806

Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806

Wood, Marie , Seisler, Drew K. , Hsieh, Meng-Kang , Kontos, Despina ... - ASCO - J. Clin. Oncol. - 2018

Abstract - Primary - Primary - Prevention - CALGB-70806